RAPP Earnings — Rapport Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
RAPP — Rapport Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$39.50
Market Cap$1.9B
P/E—
52W Range$8.20 – $42.27
Next Earnings2026-08-06
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
